Point of Care Nano-Technology, Inc. (PCNT)
USD 0.01
(0.0%)
USD 0.01
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | - USD | 0.0% |
| 2022 | - USD | 0.0% |
| 2021 | - USD | 0.0% |
| 2020 | - USD | 0.0% |
| 2015 | 95.03 Thousand USD | -4.97% |
| 2014 | 100 Thousand USD | 400.0% |
| 2013 | 20 Thousand USD | 0.0% |
| 2012 | 20 Thousand USD | 0.0% |
| 2011 | - USD | 0.0% |
| 2010 | - USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 Q1 | - USD | 0.0% |
| 2023 Q4 | - USD | 0.0% |
| 2023 Q3 | - USD | 0.0% |
| 2023 Q2 | - USD | 0.0% |
| 2023 FY | - USD | 0.0% |
| 2022 Q2 | - USD | 0.0% |
| 2022 Q4 | - USD | 0.0% |
| 2022 Q3 | - USD | 0.0% |
| 2022 FY | - USD | 0.0% |
| 2022 Q1 | - USD | 0.0% |
| 2021 FY | - USD | 0.0% |
| 2021 Q4 | - USD | 0.0% |
| 2020 FY | - USD | 0.0% |
| 2015 Q4 | 95.03 Thousand USD | -9.9% |
| 2015 Q3 | 105.47 Thousand USD | -24.91% |
| 2015 Q2 | 140.47 Thousand USD | 0.0% |
| 2015 Q1 | 140.47 Thousand USD | 11.46% |
| 2015 FY | 95.03 Thousand USD | -4.97% |
| 2014 FY | 100 Thousand USD | 400.0% |
| 2014 Q3 | 126.03 Thousand USD | 0.0% |
| 2014 Q2 | 126.03 Thousand USD | 384.11% |
| 2014 Q1 | 26.03 Thousand USD | 0.0% |
| 2014 Q4 | 126.03 Thousand USD | 0.0% |
| 2013 Q4 | 26.03 Thousand USD | 0.0% |
| 2013 FY | 20 Thousand USD | 0.0% |
| 2013 Q3 | 26.03 Thousand USD | 0.0% |
| 2013 Q2 | 26.03 Thousand USD | 30.17% |
| 2013 Q1 | 20 Thousand USD | 0.0% |
| 2012 Q1 | 10 Thousand USD | 0.0% |
| 2012 Q2 | 20 Thousand USD | 100.0% |
| 2012 Q3 | 20 Thousand USD | 0.0% |
| 2012 Q4 | 20 Thousand USD | 0.0% |
| 2012 FY | 20 Thousand USD | 0.0% |
| 2011 Q4 | - USD | 0.0% |
| 2011 FY | - USD | 0.0% |
| 2011 Q3 | - USD | 0.0% |
| 2010 FY | - USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| America Great Health | 1.87 Million USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | 274 Thousand USD | 100.0% |
| Aridis Pharmaceuticals, Inc. | 6.13 Million USD | 100.0% |
| Biora Therapeutics, Inc. | 47.42 Million USD | 100.0% |
| Bio-Path Holdings, Inc. | 113 Thousand USD | 100.0% |
| Better Therapeutics, Inc. | 14.88 Million USD | 100.0% |
| Calithera Biosciences, Inc. | 1.66 Million USD | 100.0% |
| Comera Life Sciences Holdings, Inc. | 775.04 Thousand USD | 100.0% |
| Gene Biotherapeutics, Inc. | - USD | NaN% |
| eFFECTOR Therapeutics, Inc. | 19.44 Million USD | 100.0% |
| Eloxx Pharmaceuticals, Inc. | 13.38 Million USD | 100.0% |
| Evelo Biosciences, Inc. | 51.13 Million USD | 100.0% |
| Evolutionary Genomics, Inc. | 3.74 Million USD | 100.0% |
| Finch Therapeutics Group, Inc. | 30.12 Million USD | 100.0% |
| Galera Therapeutics, Inc. | 152.29 Million USD | 100.0% |
| Innovation1 Biotech Inc. | 228.99 Thousand USD | 100.0% |
| Kiromic BioPharma, Inc. | 15.54 Million USD | 100.0% |
| Molecular Templates, Inc. | 12.23 Million USD | 100.0% |
| Navidea Biopharmaceuticals, Inc. | 2.43 Million USD | 100.0% |
| NexImmune, Inc. | 68.8 Thousand USD | 100.0% |
| Orgenesis Inc. | 22.62 Million USD | 100.0% |
| Panbela Therapeutics, Inc. | 5.19 Million USD | 100.0% |
| PaxMedica, Inc. Common Stock | - USD | NaN% |
| Scopus BioPharma Inc. | - USD | NaN% |
| Sorrento Therapeutics, Inc. | 134.5 Million USD | 100.0% |
| Statera Biopharma, Inc. | 16.26 Million USD | 100.0% |
| TRACON Pharmaceuticals, Inc. | 968 Thousand USD | 100.0% |
| Trevena, Inc. | 35.23 Million USD | 100.0% |
| Vaxxinity, Inc. | 15.16 Million USD | 100.0% |
| Vaccinex, Inc. | 247 Thousand USD | 100.0% |
| Vicapsys Life Sciences, Inc. | 353.86 Thousand USD | 100.0% |
| Viracta Therapeutics, Inc. | 25.55 Million USD | 100.0% |
| ZIVO Bioscience, Inc. | 346.34 Thousand USD | 100.0% |